Abbott announces development of novel continuous glucose-ketone monitoring system

Abbott is designing a first-of-its-kind biowearable that will enable people with diabetes to continuously monitor glucose and ketones in one sensor device promises to redefine care for people with diabetes who are at risk for developing a life-threatening complication called diabetic ketoacidosis abbott park, ill., june 3, 2022 /prnewswire/ -- abbott (nyse: abt) today announced it's developing a new biowearable that will continuously monitor glucose and ketone levels in one sensor.
ABT Ratings Summary
ABT Quant Ranking